Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Michael Davidson, Jay Saoud, Corinne Staner, Nadine Noel, Sandra Werner, Elisabeth Luthringer, David Walling, Mark Weiser, Philip D Harvey, Gregory P Strauss, Remy Luthringer, Michael Davidson, Jay Saoud, Corinne Staner, Nadine Noel, Sandra Werner, Elisabeth Luthringer, David Walling, Mark Weiser, Philip D Harvey, Gregory P Strauss, Remy Luthringer

Abstract

Background: This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar patient population.

Methods: Roluperidone 32 mg/day, roluperidone 64 mg/day, or placebo was administered for 12 weeks to 513 patients with schizophrenia with moderate to severe negative symptoms. The primary endpoint was the PANSS-derived Negative Symptom Factor Score (NSFS) and the key secondary endpoint was Personal and Social Performance scale (PSP) total score.

Results: NSFS scores were lower (improved) for roluperidone 64 mg compared to placebo and marginally missing statistical significance for the intent-to-treat (ITT) analysis data set (P ≤ .064), but reached nominal significance (P ≤ .044) for the modified-ITT (m-ITT) data set. Changes in PSP total score were statistically significantly better on roluperidone 64 mg compared to placebo for both ITT and m-ITT (P ≤ .021 and P ≤ .017, respectively).

Conclusions: Results of this trial confirm the potential of roluperidone as a treatment of negative symptoms and improving everyday functioning in patients with schizophrenia. Study registration: Eudra-CT: 2017-003333-29; NCT03397134.

Keywords: negative symptoms; schizophrenia; treatment.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Figures

Fig. 1.
Fig. 1.
Patients distribution.
Fig. 2.
Fig. 2.
PANSS Negative Symptoms Factor Score (Marder) change from baseline (MMRM) ITT population.
Fig. 3.
Fig. 3.
Personal Social Performance (PSP) total score change from baseline (MMRM) ITT population.

References

    1. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5:664–677.
    1. Robertson BR, Prestia D, Twamley EW, Patterson TL, Bowie CR, Harvey PD. Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. Schizophr Res. 2014;160:136–141.
    1. Szczypiński JJ, Gola M. Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia? Rev Neurosci. 2018;29:727–744.
    1. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692.
    1. Kirkpatrick B. Developing concepts in negative symptoms: primary vs secondary and apathy vs expression. J Clin Psychiatry. 2014;75:30–37.
    1. Culbreth AJ, Moran EK, Kandala S, Westbrook A, Barch DM. Effort, avolition, and motivational experience in schizophrenia: analysis of behavioral and neuroimaging data with relationships to daily motivational experience. Clin Psychol Sci. 2020;8:555–568.
    1. Strauss GP, Zamani Esfahlani F, Sayama H, et al. Network analysis indicates that avolition is the most central domain for the successful treatment of negative symptoms: evidence from the roluperidone randomized clinical trial. Schizophr Bull. 2020;46:964–970.
    1. Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group. Eur Psychiatry. 2000;15:321–329.
    1. Németh B, Molnár A, Akehurst R, et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017;6:639–648.
    1. Leucht S, Davis JM.Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet. 2017;389(10074):1077–1078. doi:10.1016/S0140-6736(17)30181-2.
    1. Bugarski-Kirola D, Blaettler T, Arango C, et al. Bitopertin in negative symptoms of schizophrenia—results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry. 2017;82:8–16.
    1. Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. Int J Mol Sci . 2021;22:4467.
    1. Menniti FS, Chappie TA, Schmidt CJ. PDE10A inhibitors—clinical failure or window into antipsychotic drug action? Front Neurosci. 2020;14:1–18.
    1. Katz JL, Su T-P, Hiranita T, et al. A role for sigma receptors in stimulant self administration and addiction. Pharmaceuticals. 2011;4:880–914.
    1. Lever JR, Miller DK, Green CL, et al. A selective sigma-2 receptor ligand antagonizes cocaine-induced hyperlocomotion in mice. Synapse 2014;68:73–84.
    1. Skuza G. Pharmacology of sigma (σ) receptor ligands from a behavioral perspective. Curr Pharm Des. 2012;18:863–874.
    1. Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther. 2000;292:900–911.
    1. Hayashi T, Su T-P. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol. 2005;3:267–280.
    1. Perez DM. α1-Adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Front Pharmacol. 2020;11:1–21.
    1. Davidson M, Saoud J, Staner C, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017;174:1195–1202.
    1. Rabinowitz J, Badescu S, Palamarchuk P, et al. Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019;211:103–104. doi:10.1016/j.schres.2019.07.029. PMID: 31375316.
    1. White L, Harvey PD, Opler L, Lindenmayer J. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. Psychopathology 1997;30:263–274.
    1. Marder SR, Davidson M, Zaragoza S, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia: consensus statements. Schizophrenia Bulletin Open 2020;1:sgz001.
    1. Burns T, Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand. 2007;116:403–418.
    1. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997:983–997.
    1. Khan A, Liharska L, Harvey PD, Atkins A, Ulshen D, Keefe RS. Negative symptom dimensions of the positive and negative syndrome scale across geographical regions: implications for social, linguistic, and cultural consistency. Innovat Clin Neurosci. 2017;14:30.
    1. Harvey PD, Khan A, Keefe RS. Using the positive and negative syndrome scale (PANSS) to define different domains of negative symptoms: prediction of everyday functioning by impairments in emotional expression and emotional experience. Innovat Clin Neurosci. 2017;14:18.
    1. Leucht S, Chaimani A, Mavridis D, et al. Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology. 2019;44:1955–1966.
    1. Blanchard JJ, Kring AM, Horan WP, Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37:291–299.
    1. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA psychiatry 2013;70:913–920.
    1. Luther L, Suor JH, Rosen C, Jobe TH, Faull RN, Harrow M. Clarifying the direction of impact of negative symptoms and neurocognition on prospective work functioning in psychosis: a 20-year longitudinal study. Schizophr Res. 2020;220:232–239.
    1. Davidson M. The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues Clin Neurosci. 2018;20:215–221.
    1. Harrow M, Jobe T, Faull R. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44:3007–3016.
    1. Kirkpatrick B, Saoud JB, Strauss GP, et al. The brief negative symptom scale (BNSS): sensitivity to treatment effects. Schizophr Res. 2018;197:269–273.
    1. Cohen AS, Schwartz E, Le TP, et al. Digital phenotyping of negative symptoms: the relationship to clinician ratings. Schizophr Bull. 2021;47:44–53.
    1. Dunayevich E, Chen CY, Marder SR, Rabinowitz J. Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset. Eur Neuropsychopharmacol. 2014;24:1615–1621.
    1. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2009;70:280–286.
    1. McGorry P, Alvarez-Jimenez M, Killackey E. Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 2013;70:898–900.
    1. Bogers JPAM, Hambarian G, Michielis M, et al. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia: a systematic review and meta-analysis. Schizophrenia Bull Open. 2020;1:1–12. doi:10.1093/schizbullopen/sgaa002.
    1. Murray RM, Quattrone D, Natesan S, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry. 2016;209:361–365.
    1. Strauss GP, Cohen AS. A transdiagnostic review of negative symptom phenomenology and etiology. Schizophr Bull. 2017;43:712–719.
    1. Yung AR, Nelson B, McGorry PD, Wood SJ, Lin A. Persistent negative symptoms in individuals at Ultra High Risk for psychosis. Schizophr Res. 2019;206:355–361.
    1. Strauss GP, Bartolomeo LA, Harvey PD. Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr. 2021;7:1–6.
    1. Cuthbert BN. The role of RDoC in future classification of mental disorders. Dialogues Clin Neurosci. 2020;22:81–85.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel